CD8A and neoplasm: No measurable CD8+ T cell response to TGAARFDEF (the neoepitope that elicited the strongest tumor rejection) was detected in tumor-bearing mice, even though this TRMN did elicit a robust CD8+ T cell response in non–tumor-bearing immunized mice (Figure 2D).